Advil Dual Action With Acetaminophen is a drug owned by Haleon Us Holdings Llc. It is protected by 1 US drug patent filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 09, 2041. Details of Advil Dual Action With Acetaminophen's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11918693 | Ibuprofen and acetaminophen tablet |
Jul, 2041
(16 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Advil Dual Action With Acetaminophen's patents.
Latest Legal Activities on Advil Dual Action With Acetaminophen's Patents
Given below is the list of recent legal activities going on the following patents of Advil Dual Action With Acetaminophen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical | 05 Mar, 2024 | US11918693 |
| Mail Patent eGrant Notification | 05 Mar, 2024 | US11918693 |
| Recordation of Patent eGrant | 05 Mar, 2024 | US11918693 |
| Recordation of Patent Grant Mailed Critical | 05 Mar, 2024 | US11918693 |
| Patent eGrant Notification | 05 Mar, 2024 | US11918693 |
| Email Notification Critical | 05 Mar, 2024 | US11918693 |
| Email Notification Critical | 15 Feb, 2024 | US11918693 |
| Issue Notification Mailed Critical | 14 Feb, 2024 | US11918693 |
| Dispatch to FDC | 30 Jan, 2024 | US11918693 |
| Application Is Considered Ready for Issue Critical | 30 Jan, 2024 | US11918693 |
FDA has granted several exclusivities to Advil Dual Action With Acetaminophen. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Advil Dual Action With Acetaminophen, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Advil Dual Action With Acetaminophen.
Exclusivity Information
Advil Dual Action With Acetaminophen holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Advil Dual Action With Acetaminophen's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 28, 2023 |
US patents provide insights into the exclusivity only within the United States, but Advil Dual Action With Acetaminophen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Advil Dual Action With Acetaminophen's family patents as well as insights into ongoing legal events on those patents.
Advil Dual Action With Acetaminophen's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Advil Dual Action With Acetaminophen's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 09, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Advil Dual Action With Acetaminophen Generic API suppliers:
Acetaminophen; Ibuprofen is the generic name for the brand Advil Dual Action With Acetaminophen. 7 different companies have already filed for the generic of Advil Dual Action With Acetaminophen, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Advil Dual Action With Acetaminophen's generic
Alternative Brands for Advil Dual Action With Acetaminophen
There are several other brand drugs using the same active ingredient (Acetaminophen; Ibuprofen) as Advil Dual Action With Acetaminophen. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Aft Pharms Us |
| |
| Hikma |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Acetaminophen; Ibuprofen, Advil Dual Action With Acetaminophen's active ingredient. Check the complete list of approved generic manufacturers for Advil Dual Action With Acetaminophen
About Advil Dual Action With Acetaminophen
Advil Dual Action With Acetaminophen is a drug owned by Haleon Us Holdings Llc. Advil Dual Action With Acetaminophen uses Acetaminophen; Ibuprofen as an active ingredient. Advil Dual Action With Acetaminophen was launched by Haleon Us Holdings in 2020.
Approval Date:
Advil Dual Action With Acetaminophen was approved by FDA for market use on 28 February, 2020.
Active Ingredient:
Advil Dual Action With Acetaminophen uses Acetaminophen; Ibuprofen as the active ingredient. Check out other Drugs and Companies using Acetaminophen; Ibuprofen ingredient
Dosage:
Advil Dual Action With Acetaminophen is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 250MG;125MG | TABLET | Over the counter | ORAL |